***CATALYST: Insights from the Experts to Navigate a Complex and Evolving Landscape in CLL and AML Management***

**TOOLKIT**

**Chronic Lymphocytic Leukemia (CLL)**

|  |  |
| --- | --- |
| Resource | Web Address |
| Agency for Healthcare Research and Quality (AHRQ). The SHARE Approach: A Model for Shared Decision Making. April 2016. | [www.ahrq.gov/sites/default/files/publications/files/share-approach\_factsheet.pdf](http://www.ahrq.gov/sites/default/files/publications/files/share-approach_factsheet.pdf) |
| Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): Follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21:1188-1200. | <https://pubmed.ncbi.nlm.nih.gov/32888452/> |
| American Cancer Society. Cancer Facts & Figures 2021. Accessed September 28, 2021. | <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html> |
| American Cancer Society. Chronic Lymphocytic Leukemia (CLL). Accessed September 28, 2021. | <https://www.cancer.org/cancer/chronic-lymphocytic-leukemia.html> |
| Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34:787-798. | <https://pubmed.ncbi.nlm.nih.gov/31628428/> |
| Byrd JC, Furman RR, Coutre S, et al. Up to 7 years of follow-up of single-agent ibrutinib in the phase 1b/2 PCYC-1102 trial of first line and relapsed/refractory patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Blood. 2018;132(suppl 1):3133. | <https://ashpublications.org/blood/article/132/Supplement%201/3133/263863/Up-to-7-Years-of-Follow-up-of-Single-Agent> |
| Byrd JC, Furman RR, Coutre SE, et al. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: Final analysis of the pivotal phase Ib/II PCYC-1102 study. Clin Cancer Res. 2020;26:3918-3927. | <https://pubmed.ncbi.nlm.nih.gov/32209572/> |
| Byrd JC, Harrington B, O'Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323-332. | <https://www.ncbi.nlm.nih.gov/pubmed/26641137> |
| Byrd JC, Hillmen PC, Ghia P, et al. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2021;39(15 suppl):7500. | <https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.7500> |
| Byrd JC, Woyach JA, Furman RR, et al. Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood. 2021;137(24):3327-3338. | <https://pubmed.ncbi.nlm.nih.gov/33786588/> |
| Copiktra® (duvelisib) Prescribing information. Verastem, Inc; July 2019. | <https://copiktra.com/pdf/verastem/COPIKTRA-PI-072019.pdf> |
| Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-1916. | <https://www.ncbi.nlm.nih.gov/pubmed/11136261> |
| Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928-942. | <https://pubmed.ncbi.nlm.nih.gov/27216274/> |
| Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): Final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 study). Blood. 2014;124(21):19. | <https://ashpublications.org/blood/article/124/21/19/89819/Frontline-Chemoimmunotherapy-with-Fludarabine-F> |
| Fischer K, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225-2236. | <https://www.nejm.org/doi/full/10.1056/NEJMoa1815281> |
| Flinn IW, Hillmen P, Montillo M, et al. The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132:2446-2455. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284216/> |
| Ghia P, Pluta A, Wach M, et al. Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results. J Clin Oncol. 2020;38(15 suppl):8015. | <https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.8015> |
| Ghia P, Pluta A, Wach M, et al. ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38:2849-2861. | <https://pubmed.ncbi.nlm.nih.gov/32459600/> |
| Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446-5456. | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972576/> |
| Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854. | <https://www.ncbi.nlm.nih.gov/pubmed/10477713> |
| Herman SEM, Montraveta A, Niemann CU, et al. Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia Clin Cancer Res. 2017;23:2831-2841. | <https://clincancerres.aacrjournals.org/content/23/11/2831> |
| Imbruvica® (ibrutinib). Prescribing information. Pharmacyclics LLC; December 2019. | <https://imbruvica.com/files/prescribing-information.pdf> |
| Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: An interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19:65-75. | <https://pubmed.ncbi.nlm.nih.gov/29246803/> |
| Kater AP, Wu JQ, Kipps T, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol. 2020;1;38:4042-4054. | <https://pubmed.ncbi.nlm.nih.gov/32986498/> |
| Mato AR, Roeker LE, Jacobs R, et al. Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy. Clin Cancer Res. 2020;26:3589-3596. | <https://pubmed.ncbi.nlm.nih.gov/32198151/> |
| O'Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: A 5-year experience. Blood. 2018;131:1910-1919. | <https://pubmed.ncbi.nlm.nih.gov/29437592/> |
| Roeker LE, Dreger P, Brown JR, et al. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020;4:3977-3989. | <https://pubmed.ncbi.nlm.nih.gov/32841336/> |
| Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107-1120. | <https://www.ncbi.nlm.nih.gov/pubmed/29562156> |
| Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432-443. | <https://www.nejm.org/doi/full/10.1056/nejmoa1817073> |
| Sharman JP, Coutre SE, Furman RR, et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019;37:1391-1402. | <https://pubmed.ncbi.nlm.nih.gov/30995176/> |
| Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial. Lancet. 2020;395:1278-1291. | <https://pubmed.ncbi.nlm.nih.gov/32305093/> |
| Suyko J. National Community Oncology Dispensing Association (NCODA). Positive quality intervention: Venetoclax (Venclexta®) risk stratification, dosing, and dispensing procedure. Updated September 22, 2021. | <https://www.ncoda.org/wp-content/uploads/2021/09/Venetoclax-Venclexta-Risk-Stratification-Dosing-and-Dispensing-Procedure-updated-9.22.21.pdf> |
| Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;27;379:2517-2528. | <https://pubmed.ncbi.nlm.nih.gov/30501481/> |
| Zydelig® (idelalisib). Prescribing information. Gilead Sciences, Inc; October 2020. | <https://www.gilead.com/~/media/Files/pdfs/medicines/oncology/zydelig/zydelig_pi.pdf> |